COR — Cencora, Inc.

Cencora Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Adjusted Diluted EPS: $3.84, up 15% year-over-year.
• Consolidated Revenue: $83.7 billion, a 6% increase driven by both U.S. and International Healthcare Solutions segments.
• Gross Profit: $2.9 billion, an 18% increase, with a gross profit margin of 3.47%, up 37 basis points.
• Operating Income: $1 billion, up 20% compared to the prior year quarter.
• Full Year Revenue: $321.3 billion, up 9%.
• Full Year Adjusted Free Cash Flow: $3 billion.
• Dividend: Announced a 9% increase, marking the 21st consecutive annual dividend increase.

2. Strategic Updates and Business Highlights

• Cencora is focusing on three growth priorities: leading with market leaders, enhancing patient access to pharmaceuticals, and strengthening its position in specialty.
• The company is making significant investments, including a $1 billion commitment to expand its distribution network by 2030.
• Cencora has undertaken a strategic review, resulting in the classification of certain businesses (e.g., MWI Animal Health, Profarma) under "other" for better transparency and focus on growth-oriented investments.
• The acquisition of Retina Consultants of America (RCA) has been highlighted as a key move to strengthen the specialty segment.

3. Forward Guidance and Outlook

• Fiscal 2026 Adjusted Diluted EPS Guidance: Expected to be between $17.45 and $17.75, representing growth of 9% to 11%.
• Consolidated Revenue Growth: Projected between 5% to 7%.
• Operating Income Growth: Expected to grow by 8% to 10%.
• Long-term guidance for adjusted operating income growth raised to 6% to 9% and adjusted EPS growth to 9% to 13%.

4. Challenges and Points of Concern

• The company experienced a decline in operating income in the International Healthcare Solutions segment, down 2% year-over-year, primarily due to pressures in global consulting services.
• A goodwill impairment of $724 million related to PharmaLex was noted, reflecting persistent demand challenges.
• The loss of an oncology customer due to acquisition by a peer is expected to create headwinds in the first three quarters of fiscal 2026.
• Increased net interest expense of $78 million due to debt raised for the RCA acquisition may impact profitability.

5. Notable Q&A Insights

• Management emphasized a disciplined approach to capital deployment, focusing on high-growth areas and strategic M&A, particularly in the specialty segment.
• The integration of RCA and the pathway to full ownership of OneOncology were discussed as critical to enhancing the MSO platform and driving future growth.
• Analysts raised concerns about the sustainability of high growth rates in the U.S. Healthcare Solutions segment, with management indicating confidence in maintaining strong performance despite headwinds.
• The strategic review of "other" businesses is aimed at enhancing focus and potentially divesting non-core assets, which may lead to short-term dilution but is expected to benefit long-term growth.

Overall, Cencora reported strong financial results and raised its long-term guidance, while also addressing challenges in specific segments and the strategic review of certain businesses.